Related Experiment Video
Updated: Jun 15, 2026

Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway
1Department of Internal Medicine, Institute of Clinical Sciences, Lund University, Sweden. lars.edvinsson@med.lu.se
Background:
Cerebral ischemia from middle cerebral artery wall (MCA) occlusion results in increased expression of cerebrovascular endothelin and angiotensin receptors and activation of the mitogen-activated protein kinase (MAPK) pathway, as well as reduced local cerebral blood flow and increased levels of pro-inflammatory mediators in the infarct region. In this study, we hypothesised that inhibition of the cerebrovascular inflammatory reaction with a specific MEK1/2 inhibitor (U0126) to block transcription or a combined receptor blockade would reduce infarct size and improve neurological score.
Methods:
Rats were subjected to a 2-hours middle cerebral artery occlusion (MCAO) followed by reperfusion for 48 hours. Two groups of treated animals were studied; (i) one group received intraperitoneal administration of a specific MEK1/2 inhibitor (U0126) starting at 0, 6, or 12 hours after the occlusion, and (ii) a second group received two specific receptor antagonists (a combination of the angiotensin AT1 receptor inhibitor Candesartan and the endothelin ETA receptor antagonist ZD1611), given immediately after occlusion. The middle cerebral arteries, microvessels and brain tissue were harvested; and the expressions of tumor necrosis factor-alpha (TNF-alpha), interleukin-1ss (IL-1ss), interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS) and phosphorylated ERK1/2, p38 and JNK were analysed using immunohistochemistry.
Results:
We observed an infarct volume of 25 +/- 2% of total brain volume, and reduced neurological function 2 days after MCAO followed by 48 hours of recirculation. Immunohistochemistry revealed enhanced expression of TNF-alpha, IL-1ss, IL-6 and iNOS, as well as elevated levels of phosphorylated ERK1/2 in smooth muscle cells of ischemic MCA and in associated intracerebral microvessels. U0126, given intraperitoneal at zero or 6 hours after the ischemic event, but not at 12 hours, reduced the infarct volume (11.7 +/- 2% and 15 +/- 3%, respectively), normalized pERK1/2, and prevented elevation of the expressions of TNF-alpha IL-1ss, IL-6 and iNOS. Combined inhibition of angiotensin AT1 and endothelin ETA receptors decreased the volume of brain damaged (12.3 +/- 3; P < 0.05) but only slightly reduced MCAO-induced enhanced expression of iNOS and cytokines
Conclusion:
The present study shows elevated microvascular expression of TNF-alpha, IL-1ss, IL-6 and iNOS following focal ischemia, and shows that this expression is transcriptionally regulated via the MEK/ERK pathway.
Insights
Inhibition of the MEK/ERK pathway with U0126 following cerebral ischemia significantly reduced infarct size and inflammation. Combined receptor blockade also decreased brain damage, highlighting the MEK/ERK pathway
Area of Science:
- Neuroscience
- Pharmacology
- Pathophysiology
Background:
- Middle cerebral artery (MCA) occlusion causes cerebral ischemia, leading to inflammation and receptor activation.
- The mitogen-activated protein kinase (MAPK) pathway is activated, reducing cerebral blood flow and increasing inflammatory mediators.
Purpose of the Study:
- To investigate the effect of MEK1/2 inhibitor (U0126) on cerebrovascular inflammation.
- To determine if combined angiotensin and endothelin receptor blockade reduces infarct size and improves neurological scores.
Main Methods:
- Rats underwent middle cerebral artery occlusion (MCAO) for 2 hours, followed by 48 hours of reperfusion.
- Animals received U0126 at 0, 6, or 12 hours post-occlusion, or a combination of Candesartan and ZD1611.
- Immunohistochemistry analyzed inflammatory markers (TNF-α, IL-1β, IL-6, iNOS) and phosphorylated ERK1/2.
Main Results:
- U0126 administered at 0 or 6 hours post-MCAO reduced infarct volume and normalized phosphorylated ERK1/2 levels.
- Treatment with U0126 prevented the elevation of inflammatory markers.
- Combined receptor antagonists reduced infarct volume but had minimal effect on inflammatory marker expression.
Conclusions:
- Microvascular expression of TNF-α, IL-1β, IL-6, and iNOS increases after focal ischemia.
- This inflammatory response is transcriptionally regulated by the MEK/ERK pathway.
Related Concept Videos
MAPK Signaling Cascades
Ischemic Stroke ll: Pathophysiology
Bacterial Meningitis II: Pathophysiology
Cerebral Edema ll: Pathophysiology

